June 2013

Start Page: 10
12
Author(s): 
Danielle Chicano, Editorial Associate

   According to Systagenix, the findings from the 30-patient study, which was presented at the European Wound Management Association conference in Copenhagen, Denmark, revealed that three out of four split thickness skin grafts failed in wounds that tested positive for elevated protease activity immediately prior to clinicians performing the graft procedure.

   Systagenix says these findings confirm that elevated protease activity is a highly predictive marker that could help surgeons target skin graft procedures more effectively and also support the use of the company’s Woundchek Protease Status product. Systagenix notes this product is not currently approved by the FDA in the United States.

image description image description


Post new comment

  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

More information about formatting options

Image CAPTCHA
Enter the characters shown in the image.